
-
Iranians buying supplies in Iraq tell of fear, shortages back home
-
UK's Catherine, Princess of Wales, pulls out of Royal Ascot race meeting
-
Rape trial of France's feminist icon Pelicot retold on Vienna stage
-
Khamenei says Iran will 'never surrender', warns off US
-
Oil prices dip, stocks mixed tracking Mideast unrest
-
How Paris's Seine river keeps the Louvre cool in summer
-
Welshman Thomas out of Tour of Switzerland as 'precautionary measure'
-
UN says two Iran nuclear sites destroyed in Israel strikes
-
South Africans welcome home Test champions the Proteas
-
Middle Age rents live on in German social housing legacy
-
China's AliExpress risks fine for breaching EU illegal product rules
-
Liverpool face Bournemouth in Premier League opener, Man Utd host Arsenal
-
Heatstroke alerts issued in Japan as temperatures surge
-
Liverpool to kick off Premier League title defence against Bournemouth
-
Meta offered $100 mn bonuses to poach OpenAI employees: CEO Altman
-
Spain pushes back against mooted 5% NATO spending goal
-
UK inflation dips less than expected in May
-
Energy transition: how coal mines could go solar
-
Australian mushroom murder suspect not on trial for lying: defence
-
New Zealand approves medicinal use of 'magic mushrooms'
-
Suspects in Bali murder all Australian, face death penalty: police
-
Taiwan's entrepreneurs in China feel heat from cross-Strait tensions
-
N. Korea to send army builders, deminers to Russia's Kursk
-
Sergio Ramos gives Inter a scare in Club World Cup stalemate
-
Kneecap rapper in court on terror charge over Hezbollah flag
-
Panthers rout Oilers to capture second NHL Stanley Cup in a row
-
Nearly two centuries on, quiet settles on Afghanistan's British Cemetery
-
Iran says hypersonic missiles fired at Israel as Trump demands 'unconditional surrender'
-
Oil stabilises after surge, stocks drop as Mideast crisis fuels jitters
-
Paul Marshall: Britain's anti-woke media baron
-
Inzaghi defends manner of exit from Inter to Saudi club
-
Made in Vietnam: Hanoi cracks down on fake goods as US tariffs loom
-
Longer exposure, more pollen: climate change worsens allergies
-
Sundowns edge Ulsan in front of empty stands at Club World Cup
-
China downplayed nuclear-capable missile test: classified NZ govt papers
-
Canada needs 'bold ambition' to poach top US researchers
-
US Fed set to hold rates steady as it guards against inflation
-
Sean 'Diddy' Combs trial offers fodder for influencers and YouTubers
-
New rules may not change dirty and deadly ship recycling business
-
US judge orders Trump admin to resume issuing passports for trans Americans
-
Bali flights cancelled after Indonesia volcano eruption
-
India, Canada return ambassadors as Carney, Modi look past spat
-
'What are these wars for?': Arab town in Israel shattered by Iran strike
-
Curfew lifted in LA as Trump battles for control of California troops
-
Chapo's ex-lawyer elected Mexican judge
-
Guardiola says axed Grealish needs to get 'butterflies back in his stomach'
-
Mbappe a doubt for Real's Club World Cup opener
-
Argentine ex-president Kirchner begins six-year term under house arrest
-
G7 minus Trump rallies behind Ukraine as US blocks statement
-
River Plate ease past Urawa to start Club World Cup tilt

Japan biochemist who discovered statins, Akira Endo, dies
Japanese biochemist Akira Endo, who discovered cholesterol-lowering statins, has died aged 90, his former student and colleague said on Tuesday.
Statins, which can prevent heart attacks or strokes, are among the most commonly prescribed drugs worldwide.
Keiji Hasumi, a professor who was a long-time associate of Endo, said the scientist had died on June 5.
"His work was truly great. Statins didn't exist before Endo," Hasumi told AFP. "It has the same value and impact as the discovery of penicillin."
Johns Hopkins Medicine says more than 200 million people take statins. Studies say the global market for them was worth $15 billion in 2023 and is expected to grow.
Endo experimented on thousands of microbes to reach his 1973 discovery of mevastatin -- an agent derived from penicillin that reduces so-called "bad" cholesterol in the blood.
The researcher "was a tough, strict person. He was insightful and perceptive," and "able to see the hidden essence of things", Hasumi said.
Endo was born in 1933 to a farming family in rural northern Japan.
His ambitions began early thanks to his grandfather, who was interested in medicine and became a "great home teacher", Endo said in a 2008 autobiographical essay.
As a student, Endo became interested in antibiotics like penicillin, "deeply impressed" by how many lives they had saved, his essay in the journal Nature Medicine said.
Endo carried out research in New York in the late 1960s, when coronary heart disease was the main cause of US deaths.
"I often saw ambulances coming to take elderly people who had suffered a heart attack to hospital", which "made me realise the importance of developing a cholesterol-lowering drug", he said.
Endo worked at the Tokyo University of Agriculture and Technology, which issued a statement expressing condolences over his death, and at Japanese drugmaker Sankyo, now a part of Daiichi-Sankyo.
He spent two years testing 6,000 strains of microbe in the search for a new drug that could help achieve his goal before finally finding mevastatin.
Conflicting reports on the benefits and potential harms of statins in recent years have prompted some people prescribed the drugs to stop taking them.
"Are statins safe? For most people, the answer is a resounding yes, according to a 2014 Johns Hopkins meta-analysis of 20 years worth of published research," the US university says.
Endo was a strong candidate for a Nobel Prize, but never won. In a report on his death, Japanese broadcaster NHK noted Endo had received other accolades, including being honoured as a Person of Cultural Merit by the government in 2011.
His discovery "was the result of many twists and turns", Hasumi said.
"He reached his goal by overcoming so many challenges, without which medicines cannot be created, I think I remember him saying."
A.Ruegg--VB